Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

Toripalimab

Autoimmune encephalitis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Zhou H, et al. Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab. Frontiers in Immunology 13: 25 Mar 2022. Available from: URL: http://doi.org/10.3389/fimmu.2022.850540 Zhou H, et al. Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab. Frontiers in Immunology 13: 25 Mar 2022. Available from: URL: http://​doi.​org/​10.​3389/​fimmu.​2022.​850540
Metadaten
Titel
Toripalimab
Autoimmune encephalitis: case report
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-15706-x

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Palbociclib

Case report

Denosumab

Case report

Tocilizumab

Case report

Rifampicin